Infliximab, Recombinant

Role

Indications

Reactions

Primary

Crohn's Disease	26.4%
Rheumatoid Arthritis	23.7%
Inflammatory Bowel Disease	9.5%
Colitis Ulcerative	8.5%
Product Used For Unknown Indication	7.1%
Psoriasis	6.2%
Premedication	3.8%
Ankylosing Spondylitis	3.1%
Psoriatic Arthropathy	2.8%
Hypertension	1.3%
Prophylaxis	1.0%
Gastrointestinal Disorder Therapy	1.0%
Behcet's Syndrome	1.0%
Pain	1.0%
Rheumatic Disorder	0.8%
Juvenile Arthritis	0.6%
Antibiotic Prophylaxis	0.6%
Graft Versus Host Disease	0.6%
Ill-defined Disorder	0.5%
Osteoporosis Prophylaxis	0.5%

Crohn's Disease	26.8%
Tuberculosis	6.9%
Lupus-like Syndrome	6.2%
Colitis Ulcerative	5.2%
Basal Cell Carcinoma	5.0%
Infusion Related Reaction	4.8%
Psoriasis	4.0%
Skin Cancer	3.9%
Breast Cancer	3.8%
Drug Ineffective	3.8%
Pulmonary Tuberculosis	3.8%
Herpes Zoster	3.7%
Inflammatory Bowel Disease	3.3%
Pneumonia	2.9%
Therapeutic Response Decreased	2.9%
Neoplasm Malignant	2.8%
Pyrexia	2.8%
Colectomy	2.5%
Abdominal Pain	2.4%
Coccidioidomycosis	2.4%

Secondary

Crohn's Disease	28.0%
Rheumatoid Arthritis	19.1%
Psoriasis	8.6%
Colitis Ulcerative	8.0%
Premedication	6.9%
Psoriatic Arthropathy	6.7%
Inflammatory Bowel Disease	4.5%
Ankylosing Spondylitis	3.1%
Gastrointestinal Disorder Therapy	2.1%
Prophylaxis	1.9%
Antibiotic Prophylaxis	1.8%
Hypertension	1.8%
Product Used For Unknown Indication	1.8%
Chronic Obstructive Pulmonary Disease	1.0%
Cataract	0.9%
Myocardial Infarction	0.9%
Osteoporosis Prophylaxis	0.8%
Analgesic Effect	0.7%
Cachexia	0.7%
Behcet's Syndrome	0.7%

Crohn's Disease	24.4%
Infusion Related Reaction	6.6%
Tuberculosis	6.6%
Colitis Ulcerative	5.8%
Oropharyngeal Cancer Stage Iv	5.3%
Basal Cell Carcinoma	4.7%
Small Cell Lung Cancer Stage Unspecified	4.7%
Sepsis	3.8%
Vomiting	3.8%
Breast Cancer	3.6%
Drug Ineffective	3.3%
Fibroadenoma Of Breast	3.3%
Herpes Zoster	3.3%
Abdominal Pain	3.1%
Nausea	3.1%
Colon Cancer	3.0%
Pneumonia	3.0%
Diabetes Mellitus	2.8%
Pancreatic Carcinoma	2.8%
Pneumocystis Jiroveci Pneumonia	2.8%